Kidswell Bio Company Description

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan.

Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease.

The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury.

The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021.

The company was incorporated in 2001 and is headquartered in Chuo, Japan.

Kidswell Bio Corporation

Country	Japan
Founded	2001
Industry	Biotechnology
Sector	Healthcare
Employees	37
CEO	Shinya Kurebayashi

Contact Details

Address: 3-8-3 Nihombashihoncho Chuo, 103-0023 Japan
Phone	81 3 6222 9547
Website	kidswellbio.com

Stock Details

Ticker Symbol	4584
Exchange	Tokyo Stock Exchange
Stock Type	Common Stock
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3386460004
SIC Code	2836

Key Executives

Name	Position
Shinya Kurebayashi	Chief Executive Officer